Dong J - Search Results

1

Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update.

Dong J, Qin Z, Zhang WD, Cheng G, Yehuda AG, Ashby CR Jr, Chen ZS, Cheng XD, Qin JJ. Dong J, et al. Drug Resist Updat. 2020 Mar;49:100681. doi: 10.1016/j.drup.2020.100681. Epub 2020 Jan 22. Drug Resist Updat. 2020. PMID: 32014648 Review.

2

Antimicrobial Peptide Reverses ABCB1-Mediated Chemotherapeutic Drug Resistance.

Luo X, Teng QX, Dong JY, Yang DH, Wang M, Dessie W, Qin JJ, Lei ZN, Wang JQ, Qin Z, Chen ZS. Luo X, et al. Front Pharmacol. 2020 Aug 7;11:1208. doi: 10.3389/fphar.2020.01208. eCollection 2020. Front Pharmacol. 2020. PMID: 32903706 Free PMC article.

3

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy.

Qi SM, Dong J, Xu ZY, Cheng XD, Zhang WD, Qin JJ. Qi SM, et al. Among authors: dong j. Front Pharmacol. 2021 May 7;12:692574. doi: 10.3389/fphar.2021.692574. eCollection 2021. Front Pharmacol. 2021. PMID: 34025443 Free PMC article. Review.

4

Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation.

Dong J, Cheng XD, Zhang WD, Qin JJ. Dong J, et al. J Med Chem. 2021 Jul 8;64(13):8884-8915. doi: 10.1021/acs.jmedchem.1c00629. Epub 2021 Jun 25. J Med Chem. 2021. PMID: 34170703 Review.

5

Protein degradation technology: a strategic paradigm shift in drug discovery.

Li H, Dong J, Cai M, Xu Z, Cheng XD, Qin JJ. Li H, et al. Among authors: dong j. J Hematol Oncol. 2021 Sep 6;14(1):138. doi: 10.1186/s13045-021-01146-7. J Hematol Oncol. 2021. PMID: 34488823 Free PMC article. Review.

6

Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics.

Cai M, Dong J, Li H, Qin JJ. Cai M, et al. Among authors: dong j. Curr Med Chem. 2022;29(25):4391-4409. doi: 10.2174/0929867329666220211091806. Curr Med Chem. 2022. PMID: 35152859 Review.

7

Discovery of benzochalcone derivative as a potential antigastric cancer agent targeting signal transducer and activator of transcription 3 (STAT3).

Dong J, Yang J, Yu W, Li H, Cai M, Xu JL, Xu HD, Shi YF, Guan X, Cheng XD, Qin JJ. Dong J, et al. J Enzyme Inhib Med Chem. 2022 Dec;37(1):2004-2016. doi: 10.1080/14756366.2022.2100366. J Enzyme Inhib Med Chem. 2022. PMID: 35844184 Free PMC article.

8

S3I-201 derivative incorporating naphthoquinone unit as effective STAT3 inhibitors: Design, synthesis and anti-gastric cancer evaluation.

Li H, Cai M, Cao F, Yu D, Yang J, Yu W, Chu C, Guan X, Qin JJ, Dong J. Li H, et al. Among authors: dong j. Bioorg Med Chem. 2022 Oct 1;71:116941. doi: 10.1016/j.bmc.2022.116941. Epub 2022 Jul 19. Bioorg Med Chem. 2022. PMID: 35944386

9

Design, synthesis, and biological characterization of a potent STAT3 degrader for the treatment of gastric cancer.

Li H, Wang L, Cao F, Yu D, Yang J, Yu X, Dong J, Qin JJ, Guan X. Li H, et al. Among authors: dong j. Front Pharmacol. 2022 Aug 12;13:944455. doi: 10.3389/fphar.2022.944455. eCollection 2022. Front Pharmacol. 2022. PMID: 36034876 Free PMC article.

10

Design and synthesis of proteolysis-targeting chimeras (PROTACs) as degraders of glutathione peroxidase 4.

Cai M, Ma F, Hu C, Li H, Cao F, Li Y, Dong J, Qin JJ. Cai M, et al. Among authors: dong j. Bioorg Med Chem. 2023 Jul 15;90:117352. doi: 10.1016/j.bmc.2023.117352. Epub 2023 May 26. Bioorg Med Chem. 2023. PMID: 37257255

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15,167 results

Search Page

Filters